Japanese MHLW approves Chugai Pharmas Vabysmo for neovascular AMD and diabetic macular edema

Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval today from the Ministry of Health, Labour and Welfare (MHLW) for Vabysmo for intravitreal injection 120 mg/ mL (generic name: faricimab), an anti VEGF/anti Ang-2 bispecific antibody for the treatment of "age-related macular degeneration associated with subfoveal choroidal neovascularization" and "diabetic macular edema (DME)." Age-related macular degeneration associated with subfoveal choroidal neovascularization is generally known as neovascular age-related macular degeneration (nAMD). "Vabysmo is the first bispecific antibody in ophthalmology. We are very pleased that a new therapy based on a novel mechanism of action has been approved for two diseases that may potentially lead to vision loss," said Chugai's president and CEO, Dr. Osamu Okuda. "This marks a full-scale entry into the ophthalmology field for Chugai. Vabysmo is expected to improve vision loss and reduce treatment burden by potentially offering 16-week dosing interval. We are preparing for the launch of this drug so that it can be used for treatment as soon as possible." nAMD is a disease in which age-related choroidal neovascularization grows under the retina, causing leakage of fluid and blood, resulting in retinal edema and fluid retention that leads to visual impairment. It is one of the leading causes of vision loss in people over the age of 60 worldwide, with an estimated 880,000 patients in Japan). DME is one of the complications of diabetic retinopathy and is estimated to affect more than 710,000 people in Japan). Leakage of plasma components from blood vessels in the retina causes edema in the macula, resulting in visual impairment and sometimes vision loss. Vabysmo is designed to inhibit two distinct pathways involved in many retinal diseases by blocking the actions of vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2)3). This approval is based on the results from four global phase III clinical trials (DME: Yosemite and Rhine studies, nAMD: Tenaya and Lucerne studies). These trials demonstrated non-inferiority of Vabysmo to an existing drug (aflibercept) and met their primary endpoints. In addition, for the first time in a phase III clinical trial of an intravitreal injection, Vabysmo achieved a treatment duration of up to 16 weeks interval. Adverse events in the study eye that occurred at a frequency of 0.5% or greater included intraocular inflammation (e.g., uveitis), intraocular pressure increased, retinal pigment epithelial tears, and vitreous floaters. Vabysmo (faricimab) is the first investigational bispecific antibody designed for the eye. It targets two distinct pathways

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!